Premium
Method for studying drug‐warfarin interactions
Author(s) -
Grind Margaretha,
Murphy Michael,
Warrington Steve,
Åberg Jan
Publication year - 1993
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1993.164
Subject(s) - warfarin , pharmacodynamics , pharmacokinetics , crossover study , pharmacology , placebo , medicine , drug , drug interaction , cyp2c9 , dosing , atrial fibrillation , alternative medicine , pathology , cytochrome p450 , metabolism
The potential effects of extended‐release felodipine on the pharmacokinetics and pharmacodynamics of warfarin were studied in a double‐blind crossover study in 12 healthy men. Warfarin dosage was adjusted to achieve stable subtherapeutic anticoagulation. Subjects were then randomized to receive 2 weeks of treatment with 10 mg extended‐release felodipine or placebo once daily, and warfarin dosage was adjusted if necessary to maintain stable international normalized ratio. The pharmacokinetics of R ‐and S ‐warfarin and the warfarin dose requirement did not differ importantly between periods of treatment with felodipine and placebo. The design of this study is suitable for general use in the identification of possible effects of other drugs on the pharmacokinetics and pharmacodynamics of warfarin. A different approach is needed if there is any reason to expect that warfarin may alter the pharmacokinetics or pharmacodynamics of the test drug. Clinical Pharmacology and Therapeutics (1993) 54, 381–387; doi: 10.1038/clpt.1993.164